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Mastcytosis is a rare disease characterized by an
abnormal increase of mast cells in tissues. The skin is
the organ most frequently involved, but mast cells
also accumulate in the bone marrow, gastrointestinal
tract, lymph nodes, spleen, and liver. Recent studies
suggest that activating mutations of c-kit, a proto-
oncogene encoding for the receptor (kit) of stem cell
factor, are a possible cause of some forms of masto-
cytosis. In addition, an increased rate of chromo-
somal aberrations has been found. Despite signi®cant
advances in research on mastocytosis, curative treat-
ment is not yet available. Current management is
based on avoidance of mediator-releasing triggers
and symptomatic treatment. Journal of Investigative
Dermatology Symposium Proceedings 6:143±147, 2001
EPIDEMIOLOGY
Data on the incidence of mastocytosis are still missing. One study
estimated that there are two new patients per year in a population
of 300 000, corresponding to an incidence of 0.000667%
(Rosbotham et al, 1999). Mastocytosis occurs equally in both
sexes (Golkar and Bernhard, 1997) and has been described in
different ethnic groups, although there are more reports in
Caucasians.
CLINICAL MANIFESTATIONS
The occurence of mastocytosis is usually sporadic. Yet more than
50 cases of familial occurence and several pairs of monozygotic
twins, some being concordant for mastocytosis and some discord-
ant, have been published, suggesting a heterogeneous molecular
basis of the disease (Cainelli et al, 1983; Boyano et al, 1990;
Kettelhut and Metcalfe, 1991; Pec et al, 1995; Longley et al, 1999;
Rosbotham et al, 1999; Sato-Matsumura et al, 1999).
In up to 15% of patients, the disease is congenital (Azana et al,
1994), and in a further 40% of patients, the ®rst symptoms appear
before 2 y of age (Kettelhut and Metcalfe, 1991). In adult patients,
the onset of mastocytosis most frequently occurs between the ages
of 20 and 40 y.
Mastocytosis is classi®ed into four different categories (Metcalfe,
1991a). The most common category is indolent mastocytosis that
can be subdivided into disease limited to the skin (category IA) and
systemic disease with or without cutaneous manifestation (category
IB). Category II is mastocytosis with an associated hematologic
disorder, again with or without skin involvement. Aggressive
mastocytosis (also lymphadenopathic mastocytosis with eosinophi-
lia) and mast cell leukemia are categories III and IV, respectively.
Most recently, an extended classi®cation has been proposed that
also takes the occurence of different c-kit mutations into account
(Longley and Metcalfe, 2000).
Cutaneous lesions include urticaria pigmentosa, mastocytoma,
diffuse cutaneous mastocytosis, and telangiectasia macularis eruptiva
perstans (Soter, 1991, 2000). Urticaria pigmentosa is characterized
by red-brown macules and papules, often in a symmetrical
distribution. Stroking induces erythema, wheal, and pruritus, the
so-called Darier's sign. Often, ¯ushing and pruritus are associated
with urticaria pigmentosa. Solitary or multiple mastocytomas
mainly occur in infants and present as brown macules, plaques, or
nodules. Diffuse cutaneous mastocytosis may appear as normal skin
or as yellow-brown, thickened skin with a typical orange-peel
texture. In children, blisters are often associated with diffuse
cutaneous mastocytosis. The lesions of telangiectasia macularis
eruptiva perstans present as small, red, telangiectatic macules with a
brown background.
Patients with mastocytosis often also suffer from extracutaneous
symptoms that are either caused by release of mediators from mast
cells or by mast cell accumulation in other organs such as the
skeletal system or the gastrointestinal tract (Kettelhut et al, 1989;
Horan and Austen, 1991; Topar et al, 1998). Common systemic
symptoms are musculoskeletal pain, abdominal cramping, dyspep-
sia, diarrhoea, headache, chronic fatigue, hypotension, and
anaphylactoid reactions. In about 50% of patients, increased
numbers of mast cells are found in the bone marrow (Topar et al,
1998; Czarnetzki et al, 1988). Involvement of the bone marrow
may lead to osteoporosis, spontaneous fractures, and ®brosis.
Anaemia, leukocytosis, and eosinophilia can be observed in
response to marked in®ltration of the bone marrow displacing
other cell types. Gastrointestinal involvement may be associated
with peptic ulcers, malabsorption, and gastrointestinal bleeding
(Jensen, 2000). Patients with severe systemic disease can suffer from
lymphadenopathy and hepatosplenomegaly, also causing portal
hyertension and ascites (Metcalfe, 1991b). In infants with diffuse
cutaneous mastocytosis, a more severe condition is prolonged
bleeding of the skin and the gastrointestinal tract (Kettelhut and
Metcalfe, 1991). Hematologic disorders are associated with
mastocytosis either secondary to bone marrow involvement or as
a separate entity. It has been estimated that about 10%±30% of all
patients with indolent mastocytosis develop a separate hematologic
disorder like a myeloproliferative or myelodysplastic syndrome
(category II) (Travis et al, 1988; McElroy et al, 1998; Saletti et al,
1999). Systemic mastocytosis rarely develops into an aggressive
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form (category III), where a leukemic spread of immature mast cells
in the blood may occur in the terminal stage of the disease. Very
rarely, mastocytosis presents as mast cell leukemia (category IV)
with atypical mast cells diffusely in®ltrating the bone marrow and
accounting for more than 10% of blood cells (Valent, 1996). In
contrast to aggressive mastocytosis and mast cell leukemia that are
characterized by a primary neoplastic increase of mast cells, diffuse
mast cell hyperplasia or a leukemic spread of mast cells can also
secondarily be associated with different hematologic abnormalities
(Wimazal et al, 1999).
Prognosis depends on the category of mastocytosis. For most
patients with mastocytosis, the prognosis is favorable (Kors et al,
1996). Patients with indolent mastocytosis limited to the skin have
the best prognosis. Almost all mastocytomas involute within several
years and at least 50% of children with urticaria pigmentosa
experience improvement by adulthood (Azana et al, 1994). Some
patients with indolent systemic disease may develop an additional
hematologic disorder and convert to category II mastocytosis
(Travis et al, 1988). The prognosis of these patients then depends on
the course of the hematologic disorder. With aggressive mastocy-
tosis and mast cell leukemia, median survival is less than 2 y
(Metcalfe, 1991c).
PATHOGENESIS
Activating mutations of c-kit appear to play an important role in the
pathogenesis of some forms of mastocytosis (Nagata et al, 1995;
BuÈttner et al, 1998; Worobec et al, 1998; Longley et al, 1999). The
proto-oncogene c-kit encodes a receptor tyrosine kinase (kit) that is
activated by mast cell growth factor, also known as stem cell factor
(SCF) (Taylor and Metcalfe, 2000). Kit is expressed on mast cells,
melanocytes, intraepithelial lymphoctes, gametocytes, and hema-
topoietic stem cells. Initially, two mutations in codon 816 and 560
of c-kit have been found in the human mast cell leukemia line
HMC-1 (Butter®eld et al, 1988; Furitsu et al, 1993). In murine mast
cell lines, similar mutations have been shown to cause ligand-
independent activation of kit and autonomous cell growth
(Tsujimura et al, 1994). In addition, murine cell lines with these
mutations have been described to form tumors in syngeneic mice
(Piao and Bernstein, 1996). The codon-816 mutation leads to
substitution of valine for aspartate in an activation loop within the
kinase domain of kit that controls the activity of the enzyme.
Subsequently, ligand-independent aggregation and activation of kit
may occur. In contrast, the codon-560 mutation substituting glycin
for valine belongs to a class of activating mutations that interfere
with a juxtamembrane amphipathic helix. This helical structure
negatively controls kinase activity when kit is not bound by SCF
and disruption of the juxtamembrane helix leads to constitutive
activation of kit kinase (Ma et al, 1999; Longley et al, 2000).
Most patients with adult-onset mastocytosis have been found to
carry the codon-816 mutation in circulating blood and bone
marrow cells (BuÈttner et al, 1998; Longley et al, 1999). In addition,
the codon-560 mutation has been demonstrated in several adult
patients (Vliagoftis et al, 1997; BuÈttner et al, 1998). In children, only
patients with persistent or progressive disease appear to express the
codon-816 mutation (BuÈttner et al, 1998; Longley et al, 1999).
Typical pediatric patients with indolent mastocytosis lack activating
mutations, but may express a third type of inactivating c-kit
mutations in codon 839 substituting lysine for glutamic acid
(Longley et al, 1999). Therefore, investigating the type of mutations
may in the future allow to predict a certain prognostic category for
pediatric patients (Longley and Metcalfe, 2000). In contrast to
sporadic mastocytosis, patients with familial mastocytosis fail to
express c-kit mutations, suggesting that familial mastocytosis
comprises a subgroup of the disease with a different pathogenesis
and prognosis (Longley et al, 1999; Rosbotham et al, 1999; Sato-
Matsumura et al, 1999). The recent ®ndings on c-kit mutations
have been incorporated into a new classi®cation that distinguishes
sporadic from familial mastocytosis, presence of c-kit mutations
from absence, and adult- from childhood-onset disease (Table I)
(Longley and Metcalfe, 2000). Because activation loop mutations
also appear to be more resistant to inhibition than juxtamembrane
mutations, this classi®cation scheme may in the future provide
guidelines for the treatment and prognosis of individual patients
(Ma et al, 2000).
Recent studies demonstrated that soluble kit protein correlates
with the severity of mastocytosis (Nagata et al, 1998; Akin et al
2000a, b). As soluble kit also correlates with tryptase, a marker
re¯ecting the mast cell burden, it has been speculated that the
increase of soluble kit is due to increased mast cell numbers in
mastocytosis. Soluble kit is thought to compete with membrane-
bound kit for binding to SCF and may therefore contribute to the
impaired hematopoiesis in patients with advanced mastocytosis.
Bone marrow mast cells from patients with mastocytosis are
characterized by the expression of CD2 and CD25 that are not
expressed on bone marrow mast cells from normal controls (Valent
and Bettelheim, 1992; Escribano et al, 1998). Interestingly, levels of
soluble CD25, the a-chain of the interleukin-2 receptor, also
correlate with the category and extent of mastocytosis (Akin et al,
2000b). The increase of soluble CD25 may here re¯ect the number
of activated T cells as well as mast cells. In addition, an enhanced
expression of CD35, CD63, and CD69 has been demonstrated on
bone marrow mast cells of mastocytosis patients (Escribano et al,
1995, 1999; Orfao et al, 1996; Diaz-Augustin et al, 1999), but it is
not known whether these markers play a role in the pathogenesis of
mastocytosis or whether they are due to activation of mast cells. In
one patient with mast cell leukemia, a signi®antly increased
expression of the antiapoptotic protein Bcl-2 has been found
(Cervero et al, 1999), suggesting that some forms of mastocytosis
may also be associated with inhibition of apoptosis.
Several groups also demonstrated an increased rate of chromo-
somal aberrations in mastocytosis (Lishner et al, 1996; Shekhter-
Levin et al, 1998; Worobec et al, 1998; Swolin et al, 2000). One
study suggested that patients with an associated hematologic
disorder have a greater tendency for chromosome abnormalities,
even though a correlation between cytogenetic aberrations and
Table I. Classi®cation of mastocytosis incorporating new
molecular ®ndings on c-kit mutations (modi®ed from
Longley and Metcalfe, 2000)
I. Sporadic mastocytosis with mutations affecting Kit function
A. Activation loop mutations
1. Adult (all cases have codon-816 mutation)
a. Cutaneous only
b. Systemic




c. Systemic with hematologic disorder




c. Systemic with hematologic disorder
2. Pediatric (none reported)
C. Inactivating mutations
1. Adult (none reported)
2. Pediatric






c. Systemic with hematologic disorder
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severity of mastocytosis could not be shown (Worobec et al, 1998).
Chromosomal abnormalities included deletions of chromosome 4,
5, 7, 11, and 20. The frequency and type of chromosomal
aberrations in mastocytosis is comparable with other hematologic
disorders, and may therefore re¯ect a genetic instability, possibly
with a common defective repair mechanism, of hematopoietic cells
in mastocytosis that could also be related to the different c-kit
mutations (Worobec et al, 1998; Swolin et al, 2000).
DIAGNOSIS
A typical history and characteristic cutaneous lesions with a positive
Darier's sign suggest the diagnosis of mastocytosis. The diagnosis
should then be con®rmed by a skin biopsy, in case cutaneous
involvement is present. Patients with urticaria pigmentosa show a
signi®cant, about 4±5-fold increase of dermal mast cells that can be
demonstrated by toluidine blue staining (Soter, 2000). In
mastocytomas and diffuse cutaneous mastocytosis, mast cells
in®ltrate the entire dermis, with tumor-like or band-like aggrega-
tions. All patients with suspected systemic involvement should
routinely have a complete blood count with peripheral smear to
rule out an associated hematologic disorder. Also, a bone marrow
biopsy should initially be performed in patients with suspected
systemic disease, and repeated once every 5 y or after demonstra-
tion of abnormal blood ®ndings suggesting an associated hemato-
logic disorder. Bone marrow involvement presents as nodular or
diffuse in®ltration of mast cells, sometimes associated with an
increase of other cell types such as ®broblasts, lymphocytes, and
eosinophils (Czarnetzki et al, 1988; Parker, 1991). An abdominal
ultrasound is important to rule out involvement of liver and spleen
and a bone densitometry should regularly be performed to control
for osteoporosis. Additional work-up should be tailored to
individual speci®c symptoms, e.g., gastrointestinal symptoms may
require endoscopy or musculoskeletal pain a bone scan.
Levels of serum tryptase, especially a-protryptase, and urine 1-
methyl-4-imidazole acetic acid, a metabolite of histamine, closely
correlate with the severity of mastocytosis and can therefore be
useful in con®rming a suspected diagnosis or in documenting the
individual course of the disease (Schwartz et al, 1987, 1995;
Kanthawatana et al, 1999). In contrast, histamine levels in plasma
are increased in most mastocytosis patients, but do not always
correlate with the course of mastocytosis. As detailed above, soluble
kit and soluble CD25 also correlate with the extent of mastocytosis
and may therefore additionally be used to con®rm an uncertain
diagnosis, to select patients who need a bone marrow biopsy, and to
monitor disease progression (Akin et al, 2000a, b).
TREATMENT
To date, there is no cure for patients with mastocytosis.
Therapeutic management is therefore currently aimed at symp-
tomatic treatment and avoidance of triggers that may cause systemic
mediator release and anaphylaxis. Patients should regularly be
counselled regarding mediator-releasing agents and symptoms
indicating an anaphylactoid reaction. Although studies assessing
the signi®cance of different triggering factors for mastocytosis
patients are still missing, hymenoptera stings and drugs such as
anesthetic agents appear in our personal experience to be the most
frequent causes of anaphylaxis (Hartmann and Metcalfe, 2000).
Most patients report on worsening of symptoms by sudden change
of temperature, prolonged cold or heat, alcohol, and mechanical
irritation (Table II). Recently, we conducted a survey of
mastocytosis patients (manuscript in preparation) and out of 109
patients, 62 also observed signi®cant aggravation of mastocytosis
symptoms in response to stress and 56 in response to physical
exercise. In our experience, food only plays a minor role in
inducing mediator release and we therefore do not routinely
recommend histamine-restricted diets.
All mastocytosis patients at risk of anaphylaxis should regularly
carry emergency medicines with them (antihistamines, corticoster-
oids, epinephrine). Venom immunotherapy appears to be bene®cial
in patients that had anaphylactoid reactions in response to
hymenoptera stings, even in cases without proof of venom-speci®c
IgE (MuÈller et al, 1983; Fricker et al, 1997). In all mastocytosis
categories, H1 antihistamines usually provide signi®cant relief of
pruritus, ¯ushing, whealing, bullae, and tachycardia. Adding H2
antihistamines may be bene®cial, and may also be used to control
gastric hypersecretion together with proton pump inhibitors. H1
and H2 antihistamines may prophylactically be helpful to lessen the
severity of repeated anaphylactoid reactions (Metcalfe, 1991c).
Corticosteroids improve malabsorption, ascites, and bone pain and
can also prevent or ameliorate anaphylaxis. Cromolyn sodium is
used to control abdominal cramping, nausea, and diarrhoea
(Czarnetzki and Behrendt, 1981; Horan et al, 1990). Aspirin and
other nonsteroidal agents appear to improve ¯ushing in some
patients, although aspirin has also been reported to aggravate
symptoms of mastocytosis in other patients. Oral PUVA and high-
dose UVA1 phototherapy lead to amelioration of pruritus and
whealing as well as fading of cutaneous lesions (Czarnetzki et al,
1985; Stege et al, 1996); however, relapses usually occur within 3±6
mo of cessation of treatment. One study reported on transiently
decreased mast cell numbers in response to PUVA irradiation
(Kolde et al, 1984). Mastocytomas that fail to involute spontan-
eously or that are associated with systemic symptoms can be
removed surgically or treated with potent topical corticosteroids
under occlusive dressings (Metcalfe, 1991c). Interferon a-2b and -
2a have been used with mixed results to treat patients with systemic
mastocytosis. Several groups observed improvement of various
symptoms such as pruritus, ¯ushing, diarrhea, and abdominal pain
after administration of interferon a (Kluin-Nelemans et al, 1993;
Czarnetzki et al, 1994; Lippert and Henz, 1996; Butter®eld, 1998);
however, other studies failed to demonstrate a bene®cial effect of
interferon a on mastocytosis (Worobec et al, 1996; De las Nieves et
al, 1997). The only subgroup in which interferon a in several
studies consistently showed improvement are patients with severe
osteoporosis and osteopenia that fail to respond to other therapies
(Lehmann et al, 1996; Weide et al, 1996; Worobec, 2000). In
patients with disease of categories II±IV, classical chemotherapeutic
regimens usually have no effect on the course of mastocytosis, but
may improve an associated hematologic disorder (Travis et al, 1986;
Metcalfe, 1991c). Probably due to a slow cell cycle and prolonged
survival, mast cells appear to be relatively resistant to chemother-
apeutic agents. There are only exceptional cases that responded to
chemotherapy, as summarized in detail by Worobec (2000).
Future strategies to treat mastocytosis patients may include
targeting the kit receptor (Longley et al, 2000; Worobec, 2000). In
fact, recent in vitro studies have been able to demonstrate killing of
neoplastic mast cells by indolinone derivatives that inhibit kit kinase
(Ma et al, 2000). Kit is, however, also expressed on other cell types
and kit kinase inhibitors could therefore in vivo have serious side-
effects, especially on hematopoietic stem cells. A further under-
standing of survival and cell cycle control of neoplastic mast cells, of
speci®c mast cell receptors, and of signal transduction pathways in
aberrant mast cells may help to develop treatment strategies aimed
at targeting the cause of mastocytosis.
Table II. Triggering factors that can induce release of mast
cell mediators in patients with mastocytosis
Insect stings, poison (hymenoptera, jelly®sh, snakes)
Drugs (codeine, morphine, pethidine, dextran, iodinated radiocontrast
dyes, adrenergic and cholinergic receptor antagonists)
Sudden change of temperature, prolonged heat, prolonged cold
Stress, physical exercise
Alcohol
Mechanical irritation (friction, pressure)
Infections (viral, bacterial)
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